AI
ACHN

Axiom Investors’s Achillion Pharmaceuticals ACHN Stock Holding History

Axiom Investors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-64,250
Closed -$634K – 161
2015
Q1 		$634K Sell
64,250
-400
-0.6% -$5K 0.02% 135
2014
Q4 		$792K Buy
64,650
+8,360
+15% +$102K 0.02% 147
2014
Q3 		$562K Buy
+56,290
New +$522K 0.01% 150

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Axiom Investors's ACHN Position: Q2 2015 in Review

Axiom Investors sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 64,250 shares — an estimated $634K sold.

Axiom Investors first reported a position in ACHN in Q3 2014 and held it in 3 quarters. The position peaked at $792K in Q4 2014. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Axiom Investors reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Axiom Investors sold 64,250 Achillion Pharmaceuticals shares in Q2 2015, an estimated $634K.
  • Axiom Investors first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Axiom Investors's Achillion Pharmaceuticals position peaked at $792K in Q4 2014.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Axiom Investors's 13F filing for Q2 2015, filed 13 Aug 2015.